• CDM Monthly Review (November 2023, Issue 75)

    Hello experts and colleagues, in this 75th issue of the CDM Monthly Review for November 2023, we share six recent publications in the field of portal hypertension diagnosis and treatment (three on diagnosis and monitoring, and three on multidisciplinary treatment). This issue features guest experts: Dr. Bingtian Dong from the Department of Ultrasound at the…

  • Application of Ultrasound Elastography Scoring in Diagnosing Potential Porto-Sinusoidal Vascular Disease in Patients with Portal Vein Thrombosis

    The “Hepatology Digest-Vascular Liver Disease Column” is an academic column jointly initiated by Dr. Xingshun Qi of the Department of Gastroenterology, Northern Theater Command General Hospital, at the invitation of the editorial department of ” Hepatology Digest”. This column regularly collects and organizes research progress in the field of vascular liver disease. Every two weeks…

  • From “Clinical Cure” to “Disease Cure” – The Long-term Treatment of Chronic Hepatitis B

    From November 17-19, 2023, the “15th Chronic Viral Hepatitis Antiviral Treatment Difficulties and Hotspots Academic Conference” was grandly held in Chongqing. Sponsored by the Chinese Medical Journal Co., Ltd., organized by the Editorial Department of the Chinese Journal of Hepatology, and co-organized by the Hepatitis Group of the Chinese Society of Hepatology of the Chinese…

  • Construction and Validation of a Hepatocellular Carcinoma Prognosis Model Based on Stress Granules

    In an effort to keep clinicians and researchers in the field of hepatology abreast of the latest academic knowledge and research trends, ” Hepatology Digest ” has collaborated with the “Journal of Clinical and Translational Hepatology” (JCTH) to introduce the “Journal Co-Read” section. Each week, this section selects and interprets highlights from a key publication,…

  • Efficacy Analysis of “T+A” Therapy in Different Treatment Populations of HCC

    Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Most patients are unable to undergo surgical resection at the time of diagnosis, making systemic therapy an important treatment approach for this group. The combination immunotherapy of Atezolizumab plus Bevacizumab (“T+A”) has become the new first-line standard treatment for unresectable HCC patients due…

  • Progress and considerations in the research of malnutrition in patients with cirrhosis

    Malnutrition, a subacute or chronic nutritional condition, arises from insufficient (or excessive) food intake and/or inflammation, leading to compromised body composition and reduced bodily functions, adversely affecting clinical outcomes and prognosis. Given the liver’s central role in metabolizing glucose, proteins, and fats, patients with ongoing liver damage, especially cirrhosis, commonly suffer from malnutrition. Studies indicate…

  • Dr. Massimo Federico: 10-Year Follow-up Results of Early FDG-PET Adaptive Treatment for Limited-Stage HL

    At the International Malignant Lymphoma Conference (ICML 2023), Dr. Massimo Federico from University of Modena and Reggio Emilia, presented a captivating report on 10-Year Follow-up Analysis of the EORTC/LYSA/FIL H10 Randomized Intergroup Trial during the “Focus on Hodgkin Lymphoma” session. Oncology Frontier specially invited Dr. Federico for an in-depth interview on this topic.

  • Dr. Xu Pengpeng: Preliminary Results of Targeted Drug Combination with CHOP as First-Line Treatment for PTCL

    Peripheral T-cell lymphoma (PTCL) is a heterogeneous disease with poor prognosis. Standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy is the most widely used regimen for first-line treatment of PTCL.…